Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
---|
01/31/2002 | US20020013957 Genetically engineering swine embryos; culture swine embryos, translocate nucleus to another swine embryo, activate oocyte, monitor embryo development |
01/31/2002 | US20020013956 Meiotic recombination in vivo of partially homologous dna sequences |
01/31/2002 | US20020013955 Production of recombinant protein in transgenic fish |
01/31/2002 | US20020013954 Whole-body optical imaging of gene expression and uses thereof |
01/31/2002 | US20020013953 Transgenic mammal; for use as model in evaluating lysosomal storage defects |
01/31/2002 | US20020013952 Self-contained system for sustained viral replication |
01/31/2002 | US20020013458 Enzymatic nucleic acid treatment of disases or conditions related to hepatitis c virus infection |
01/31/2002 | US20020013456 Cortistatin: neuropeptides, compositions and methods |
01/31/2002 | US20020013455 Isolation and identification of novel polymerases |
01/31/2002 | US20020013452 Nucleotide sequences coding cytokine; for use in cancer treatment |
01/31/2002 | US20020013285 Nucleosome-based anti-tumor compositions |
01/31/2002 | US20020013283 Bombarding a plant or animal cell with a microparticle of a composite of a metal support, a dendritic polymer and the genetic material; high density; efficiency; delivering higher quantities of genetic materials with less damage |
01/31/2002 | US20020013282 Transfecting a cell comprising by contacting the cell with a biologically active nucleic acid molecule in the presence of a cationic lipid which can be protonated; cationic amphiphiles to transport drugs into cells; gene therapy |
01/31/2002 | US20020012998 Gene transfer composition; for use in the transfection of mammalian cells |
01/31/2002 | US20020012997 Transducing cell; incubate cells with nucleotide sequences, insert cells into mammals, monitor mammals for phenotypic adjustment |
01/31/2002 | US20020012996 Mutating genes; mix cell and vector, transform mammalian cells, recover cells |
01/31/2002 | US20020012995 Negative-sense RNA virus vector for nerve cell |
01/31/2002 | US20020012993 Improved immortalized human skin cell lines and novel serum-free medium useful for the production thereof |
01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
01/31/2002 | US20020012991 Nutrient broth; for use in the generation of monoclonal antibodies and preferential particles; for use in maintenance of cell viability |
01/31/2002 | US20020012990 Isolation of nucleotide sequences cell lysate; extract coiled nucleotide sequences, precipitate coiled nucleotide sequences, isolate coiled nucleotide sequences |
01/31/2002 | US20020012989 Genetically engineered nucleotide sequences coding preferential proteins for use in treatment of viral disease |
01/31/2002 | US20020012984 Genetic engineering |
01/31/2002 | US20020012983 Novel subunits of nadh dehydrogenase |
01/31/2002 | US20020012981 Plant protein; for use in the development of disease rsistance plants |
01/31/2002 | US20020012979 Biosynthesis; using isomerization enzyme |
01/31/2002 | US20020012974 Methods for producing enantiomerically pure alpha-substituted carboxylic acids |
01/31/2002 | US20020012972 Optimally labeled oligonucleotides |
01/31/2002 | US20020012971 Containing polymer |
01/31/2002 | US20020012970 Amplification of nucleotide sequences; provide mix which contains nucleotide sequences and polymerase, amplify nucleotide sequences, recover nucleotide sequences |
01/31/2002 | US20020012969 Method of quantifying tumour cells in a body fluid and a suitable test kit |
01/31/2002 | US20020012966 18 Human secreted proteins |
01/31/2002 | US20020012965 Nucleotide sequences coding prfeerential polypeptides for use in the diagnosis and treatment of brain disorders and injury |
01/31/2002 | US20020012964 Polypeptide for use in the diagnosis and treatment of cancer |
01/31/2002 | US20020012963 Nucleotide sequences coding preferential peptides; for use in diagnosing and treatment of allergies |
01/31/2002 | US20020012962 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia |
01/31/2002 | US20020012940 Monitoring preferential expression; provide a pool of target ribonucleic acid sequences, hybridize to immobilized probes, measure nucleic acid hybridization to soild support |
01/31/2002 | US20020012939 Methods for identifying drug targets based on genomic sequence data |
01/31/2002 | US20020012936 Test sample treated with a base and incubated with nucleic acid probes, diluted in a neutralizing buffer, specific for target nucleic acids. The hybrids are captured onto a solid phase coated with an anti-hybrid antibody fragment |
01/31/2002 | US20020012935 Composition for the generation biochips or a substrate immobilized with a biopolymer |
01/31/2002 | US20020012933 Annealing a population of circular nucleic acid molecules to a anchor primers linked to a solid support, and amplifying those molecules which anneal to the target nucleic acid, and then sequencing the amplified molecules |
01/31/2002 | US20020012931 High specificity marker detection |
01/31/2002 | US20020012930 Method of sequencing a nucleic acid |
01/31/2002 | US20020012928 Method for synthesis of nucleic acids |
01/31/2002 | US20020012924 Isolating preferential nucleotide sequences; provide nucleotide sequences, mix with oligonucleotide support, monitor support for hybridization signals |
01/31/2002 | US20020012922 Simultaneous sequence-specific identification and display of mRNA molecules in RNA population. |
01/31/2002 | US20020012918 Methods and compositions for detection of mycobacterium avium complex species |
01/31/2002 | US20020012916 A method of reducing contamination in an essay vessel |
01/31/2002 | US20020012915 Hybridizing at least one selected single strand sequence with a complementary single strand nucleic acid and a crosslinking agent; COBRA method for the labeling of a set of bio-organic molecules with a set of colors |
01/31/2002 | US20020012914 Transfection of preferential nucleotide sequences into aggregations; mix sample and nucleotide sequences, incubate, expose to electric pulse, recover transformed aggregations |
01/31/2002 | US20020012913 Detecting polymorphism in preferential nucleotide sequences; provide probe arrays, hybridize target nucleotide sequences and determine pattern, hybridize control and determine pattern, compare patterns and detect polymorphism |
01/31/2002 | US20020012909 Small functional units of antibody heavy chain variable regions |
01/31/2002 | US20020012905 Generating profile of preferential chemical intermediates; incubate liver stem cells with chemical intermediate, monitor cells, detect adjustments in gene expression, classify respones to chemical intermediate |
01/31/2002 | US20020012903 Separating neuronal pluripotent stem cells from mixed sample of cells; transform cells, express marker, recover cells expressing marker |
01/31/2002 | US20020012902 Methods and kit for hybridization analysis using peptide nucleic acid probes |
01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
01/31/2002 | US20020012669 For detecting a genetic abnormality, cancer |
01/31/2002 | US20020012668 Used in diagnostics, detection of the bacteria Salmonella.typhi or in the production of vaccines for typhoid fever |
01/31/2002 | US20020012664 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian CC-chemokine receptor 2, mammalian CC-chemokine receptor 2 or ligand-binding variant, measuring binding |
01/31/2002 | US20020012661 Methods for introducing genes into mammalian subjects |
01/31/2002 | US20020012660 Method of preparing a somatic cells for nuclear transfer |
01/31/2002 | US20020012656 Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses |
01/31/2002 | US20020012655 Administering to or transplanting into least one cell or tissue obtained from cloned ungulate animal or embryo for therapy |
01/31/2002 | US20020012616 Fluidic methods and devices for parallel chemical reactions |
01/31/2002 | US20020012456 Method and apparatus for providing a bioinformatics database |
01/31/2002 | EP1144610A3 Method for carrying out the controlled post-harvest production of proteins in host organisms |
01/31/2002 | DE10103874A1 Verfahren zur fermentativen Herstellung von L-Threonin A process for the fermentative preparation of L-threonine |
01/31/2002 | DE10035953A1 Sphärische, magnetische Silica-Partikel mit einstellbarer Teilchen- und Porengröße sowie einstellbarem Magnetgehalt für die Aufreinigung von Nukleinsäuren und anderen Biomolekülen Spherical magnetic silica particles with adjustable particle and pore size as well as an adjustable magnetic content for purification of nucleic acids and other biomolecules |
01/31/2002 | DE10034804A1 Verwendung von VLCFAE zum Identifizieren von herbizid wirksamen Verbindungen Using VLCFAE for identifying herbicidally active compounds |
01/31/2002 | DE10033750A1 Pathogenresistenz in Organismen Pathogen resistance in organisms |
01/31/2002 | DE10032402A1 New peptide variants of the MUC1 tumor marker, useful for antitumor immunization and preparation of diagnostic antibodies |
01/31/2002 | DE10031179A1 Introducing active molecules into the nucleus of eukaryotic cells, useful for transfection and gene therapy, by applying controlled electrical pulse |
01/31/2002 | CA2797652A1 Multi-component biological transport systems |
01/31/2002 | CA2427824A1 Human cytokine receptor |
01/31/2002 | CA2418333A1 Bicistronic influenza comprising two genes in tandem |
01/31/2002 | CA2418282A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
01/31/2002 | CA2418198A1 Novel protein containing ring finger domaine r1p4 |
01/31/2002 | CA2418179A1 The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity |
01/31/2002 | CA2417508A1 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
01/31/2002 | CA2417223A1 A novel member of the epha receptor family |
01/31/2002 | CA2417185A1 Multivalent target binding protein |
01/31/2002 | CA2417130A1 Glycerol-3-phosphate/dihydroxyacetone phosphate dual substrate acyltransferases |
01/31/2002 | CA2417075A1 Detection of abnormalities leading to cervical malignancy |
01/31/2002 | CA2417010A1 Controlled environment agriculture bioreactor for heterologous protein production |
01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
01/31/2002 | CA2416789A1 Methods for analysis and identification of transcribed genes, and finger printing |
01/31/2002 | CA2416764A1 Methods, systems, and articles of manufacture for evaluating biological data |
01/31/2002 | CA2416733A1 Nk cells activating receptors and their therapeutic and diagnostic uses |
01/31/2002 | CA2416713A1 Novel siglecs and uses thereof |
01/31/2002 | CA2416701A1 Methods for the replacement, translocation and stacking of dna in eukaryotic genomes |
01/31/2002 | CA2416691A1 Proteases |
01/31/2002 | CA2416684A1 General means of labeling protein by using wheat embryo cell-free protein synthesis system |
01/31/2002 | CA2416683A1 Dog melanin-concentrating hormone receptor |
01/31/2002 | CA2416676A1 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
01/31/2002 | CA2416664A1 Zinc finger domain recognition code and uses thereof |
01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
01/31/2002 | CA2416611A1 Methods and systems for evaluating a matching between measured data and standards |
01/31/2002 | CA2416558A1 Plant acyl-coa synthetases |
01/31/2002 | CA2416548A1 Artificial vascular grafts, and methods of producing and using same |